Лоспирин

Quick links to important sections

Лоспирин

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Лоспирин

What is Lospirin?

Property Description
Active Ingredient Acetylsalicylic Acid (ASA)
Form Enteric-Coated Tablets
Pharmacological Class Antiplatelet Agent (Blood Thinner)
Primary Purpose Cardiovascular Prophylaxis (Prevention)
Origin Synthetic Compound

Lospirin is a specific, commercially available brand formulation of the active ingredient Acetylsalicylic Acid (ASA), primarily used for long-term preventative purposes in cardiology. It is an oral medication taken as enteric-coated tablets. This coating is a key differentiating feature, strategically designed to delay the dissolution of the ASA until it reaches the small intestine, which is intended to help reduce the risk of stomach irritation compared to non-coated forms.


To Which Drug Class Does Lospirin Belong?

Lospirin belongs to the pharmacological class of Antiplatelet Agents, which is its functional category at the small doses utilized. Its active component, ASA (a synthetic compound), is also molecularly classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). However, the product's focus is on delivering a precise, low-dose concentration to leverage its anti-aggregant effect. ASA works primarily by blocking an enzyme needed for platelet aggregation.


What is Lospirin's General Therapeutic Purpose?

The primary therapeutic purpose of Lospirin is the long-term prophylaxis (prevention) of thrombotic events in individuals at high risk for serious cardiovascular issues. Its function relies entirely on its continuous anti-aggregant effect, which makes the platelets in the blood less prone to clumping together. Acetylsalicylic Acid serves a critical role in cardiovascular disease prevention through this mechanism.

What side effects are possible with Лоспирин?

Possible Side Effects and Safety Information

The official safety profile for Acetylsalicylic Acid (ASA), the active ingredient in Lospirin, is primarily structured around its antiplatelet function and its effects on the gastrointestinal system. Adverse reactions are classified by frequency and categorized by system-organ class as documented in regulatory sources.


Adverse Reaction Scope

Category Description
Key Adverse Reaction Categories Bleeding (hemorrhage), Gastrointestinal (GI) disturbances, and Hypersensitivity reactions.
Frequency Classification Common effects include GI symptoms like dyspepsia and increased bleeding tendency. Rare events include major hemorrhage and severe GI ulceration.
System-Organ Classes Involved Blood and lymphatic system disorders (risk of hemorrhage); Gastrointestinal disorders (e.g., ulceration, nausea); Immune system disorders (hypersensitivity reactions).
Serious Adverse Reactions Officially documented serious risks include Major Hemorrhage (intracranial or gastrointestinal) and the rare, but severe, Reye's Syndrome associated with pediatric use during viral illness.

Safety Considerations and Constraints

Specific population and duration-related constraints are defined in regulatory labeling. The risk of serious GI complications, such as bleeding or ulceration, is noted to be associated with long-term use.

Official labeling notes contraindications for individuals with active pathological bleeding (such as an active peptic ulcer), known severe hypersensitivity to ASA or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and generally advises against use during the third trimester of pregnancy.

Regulatory Safety Summary

The central safety element is the officially documented risk of bleeding and hemorrhage. The common adverse reactions are typically Gastrointestinal disorders. The most restrictive warnings concern use in pediatrics and patients with severe hepatic or renal impairment.

This information establishes that while the expected effects are often related to GI discomfort, the most critical risks are directly linked to the drug's antiplatelet action, defining the clinical boundaries of its acceptable use.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that a suspected overdose of Лоспирин (Lospririn) requires immediate medical attention.

Documented Overdose Manifestations

Symptoms of toxicity, based on documented profiles, can range from mild to severe, and may present differently in acute versus chronic exposure. Initial signs often include tinnitus (ringing in the ears), nausea, vomiting, dizziness, and rapid, deep breathing (hyperventilation).

Severe manifestations documented in regulatory sources include central nervous system effects such as seizures and coma, as well as severe metabolic disturbances like profound metabolic acidosis and fluid buildup in the lungs (pulmonary edema).

Emergency Response and Management

Overdose Action Regulatory Requirement
Seeking Help Get medical help or contact a Poison Control Center right away for any suspected overdose.
Monitoring Requires serial measurements of drug levels and continuous assessment of acid-base status and electrolytes.
Intervention Management may include decontamination using activated charcoal, supportive care to correct dehydration, and specialized procedures like urinary alkalinization or hemodialysis for severe poisoning.

Population-Specific Considerations

Regulatory warnings note that individuals with underlying conditions, such as kidney or respiratory impairment, face increased risk of severe toxicity. The elderly are notably susceptible to chronic toxicity, which may present subtly as confusion or delirium. Due to high toxicity risk, ingestion by children is considered a medical emergency.

Therapeutic Uses of Лоспирин

What Лоспирин Treats: Main Uses and Benefits

The primary therapeutic role of Lospirin (low-dose Acetylsalicylic Acid) is the long-term management and reducing the risk of severe cardiovascular events in individuals at high risk due to established vascular disease. It generally provides supportive prophylaxis by contributing to the management of conditions marked by potential vascular events. The use of its active component is associated with a reduced risk of major nonfatal vascular events in high-risk patients.

Lospirin is commonly used for management of conditions that may involve episodic or fluctuating manifestations. These indications primarily include the secondary management of patients who have already experienced a Myocardial Infarction or Ischemic Stroke, as well as the ongoing care for individuals with Chronic Atherosclerotic Cardiovascular Disease (ASCVD), stable or unstable angina, and Peripheral Arterial Disease (PAD). It is also applied in specific post-surgical prophylaxis scenarios following coronary stent placement or bypass grafting.

“The primary goal of this therapy is to help patients cope more steadily with the high recurrence vulnerability related to established vascular disease.”

Quick Fact: Assistance for Chronic Vulnerability

Quick Fact: Assistance for Chronic Vulnerability
This medication supports patients during difficult episodes by easing distress and contributing to easing the overall symptom load, particularly in high-risk adults and those with a history of vascular events.

Eligibility and Restrictions for Use

Eligibility for Лоспирин (Low-Dose Acetylsalicylic Acid)

Official regulatory documents define specific populations who are permitted, restricted, or absolutely prohibited from using Лоспирин (low-dose Acetylsalicylic Acid/ASA).

Contraindicated Populations (Must Not Use): Use is strictly prohibited for patients with a known hypersensitivity to Acetylsalicylic Acid or any NSAID, or those with active pathological bleeding, such as a peptic ulcer or established bleeding disorder. The medicine is also contraindicated in patients with severe hepatic impairment, severe renal impairment, and during the third trimester of pregnancy.

Restricted or Conditional Use: Use is not recommended for children and teenagers with viral symptoms due to the risk of Reye's syndrome; pediatric use for cardiovascular prophylaxis is not established. Use is generally restricted or requires close medical supervision in breastfeeding mothers and patients with mild-to-moderate hepatic or renal impairment. Older adults are permitted to use the medicine but may require caution due to an increased risk of complications, such as gastrointestinal bleeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lospirin’s official interaction profile is defined by two primary regulatory concerns: the potential for severe bleeding and the alteration of other drug levels. The following information is based strictly on authoritative government regulatory documentation.

Pharmacodynamic Interactions and Bleeding Risk

Co-administration with other anti-clotting agents, including Anticoagulants (such as Warfarin) and Other Antiplatelet Agents, creates a formally documented increased risk of hemorrhage. Similarly, combining Lospirin with Selective Serotonin Reuptake Inhibitors (SSRIs) or Systemic Corticosteroids augments the risk of gastrointestinal bleeding.

Exposure and Effect Modification

Regulatory documents state that Lospirin can affect the circulating levels of specific medicines. It is documented to inhibit the renal clearance of Methotrexate, leading to increased drug concentrations and potential toxicity, a risk heightened in elderly or renal-impaired patients. Furthermore, its salicylate component may displace Valproic Acid and Phenytoin from plasma proteins, altering their levels. Co-administration with certain Antihypertensive Agents may diminish their intended blood pressure-lowering effect.

Restrictions and Conditions

  • Timing Rule: To prevent the antagonism of the antiplatelet effect, Ibuprofen must be separated from immediate-release ASA by at least 8 hours before or 30 minutes after the ASA dose.
  • Alcohol Use: The consumption of three or more alcoholic drinks every day is officially stated to increase the chance of serious gastrointestinal bleeding.
  • Contraindicated Class: The use of Lospirin is restricted in patients with Aspirin-Exacerbated Respiratory Disease (AERD) when co-administering other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Mechanism of Action

How Лоспирин Works

Лоспирин functions as an irreversible inhibitor of Cyclooxygenase (COX) enzymes, targeting both COX-1 and COX-2 isoforms. The drug's active component achieves this by the acetylation of a serine residue within the enzyme's active site. This chemical modification permanently prevents the enzyme from catalyzing the conversion of arachidonic acid into various pro-inflammatory and pro-aggregatory lipid mediators.

The resulting molecular cascade is most pronounced in circulating platelets, which are anucleated and cannot synthesize new COX-1 enzyme to replace the inhibited molecules. This leads to a sustained blockade of Thromboxane A2 ( TXA2) synthesis for the life of the platelet. This TXA2 suppression alters the balance of pro-aggregatory and anti-aggregatory signals by reducing the rate of TXA2-mediated platelet activation.

Simultaneously, the inhibition of COX-2 and COX-1 impacts the synthesis of prostaglandins. This action decreases the quantity of pro-inflammatory prostaglandin mediators associated with peripheral inflammatory signaling.

Dosage and Administration Information

Instruction Map: How to use Лоспирин — Administration Guidelines

This map consolidates the high-level instructions for the use of low-dose Acetylsalicylic Acid (ASA) in cardiovascular prophylaxis.


Administration Scope

Category Instruction Entity
Route of administration Oral administration only.
Dosing schedule The standard maintenance dose ranges from 75 mg to 162 mg of ASA once daily. Initial, short-term loading doses up to 325 mg may precede the maintenance phase.
Timing in relation to meals (if applicable) The tablet should be taken with or immediately after food and a full glass of water.
Preparation requirements (if applicable) Swallow the Enteric-Coated Tablet whole; it must not be cut, crushed, or chewed to ensure the integrity of the delayed-release formulation.
Age-group administration rules The usual adult dose is applied in the absence of severe renal or hepatic insufficiency. It is generally not indicated for use in persons under the age of 16.
Missed-dose rules If a dose is missed, it should be taken as soon as remembered on the same day. Patients are instructed not to take a double dose on the subsequent day to compensate.
Special procedural conditions The use pattern is designated as long-term or indefinite for chronic prophylactic management.

Instruction Classifications (High-Level)

Classification Pattern
Administration method type Oral administration (PO).
Frequency pattern Once Daily (qDay) for continuous effect.
Basis of use Standardized clinical parameters.
Use-context constraints Long-term/Indefinite duration for chronic management.

Resulting procedural structure

Step sequence:

  • Confirm the standard dose (75–162 mg) and schedule is once daily.
  • Take the tablet with or immediately after food and water.
  • Swallow the enteric-coated tablet whole without altering its form.

Connection to the overall use protocol (2–4 sentences):

The administration protocol is defined by the need for continuous antiplatelet action, mandating a once-daily oral dose taken for an indefinite duration. The procedural constraint to swallow the enteric-coated form whole is essential to preserve the drug's specialized release profile, thereby standardizing its intended use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Лоспирин

The evidence for low-dose aspirin, the active substance in Лоспирин, focuses on research that explored outcomes related to serious cardiovascular events. The research includes many large, long-term studies and collaborative analyses that describe patterns observed in the use of this therapy. It is important to remember that these findings describe group patterns, not personal outcomes, and research provides context but not individual predictions.


Evidence for Primary Prevention of Cardiovascular Events

Large Randomized Controlled Trials (RCTs) and systematic reviews explored the practice of beginning low-dose aspirin in adults who had no history of a heart attack or stroke. These studies primarily monitored patient outcomes related to major composite vascular events and safety outcomes. In these trials, findings describe patterns observed in the studies where the occurrence of nonfatal heart attacks was observed at a lower rate in the groups using low-dose aspirin compared to those not using it. However, the same research consistently reported measurements of an increase in the occurrence of major bleeding events in the aspirin groups. For some outcomes, such as all-cause death, the data show patterns related to findings that were mixed or inconclusive.


Evidence for Secondary Prevention of Cardiovascular Events

The core evidence supporting the use of Лоспирин in patients who have experienced a prior event, like a heart attack or an ischemic stroke, was studied for outcomes related to recurrence rates. This research includes numerous large RCTs and comprehensive meta-analyses. The studies explored outcomes related to recurrent nonfatal heart attacks and subsequent strokes. These trials describe patterns showing differences in the frequency of recurrent vascular events in the groups using low-dose aspirin compared to control groups.


What is Still Uncertain About Лоспирин Research

A major area of uncertainty is the precise method for determining which individuals in the primary prevention setting may show a favorable outcome when considering the studied vascular events and the measured bleeding risk. The comparative evidence is lacking for many new antiplatelet regimens. Long-term effects are not fully established beyond the observation periods of the largest controlled studies. Ongoing research is ongoing to better define the optimal strategy for various patient risk categories.

Key Studies & References

  1. Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication (U.S. Preventive Services Task Force - 2022 Recommendation Statement)

Frequently Asked Questions (FAQ)

Common questions about Лоспирин (FAQ)

Q: Can I take Лоспирин if I have stomach issues like gastritis?

A: Official product information advises caution or may contraindicate the use of aspirin if a person has active or previous gastrointestinal issues, such as ulcers, bleeding, or other digestive disorders like gastritis. This is because of the documented risk of stomach bleeding associated with the medication. A healthcare provider must assess an individual's history of stomach issues to determine if this medicine is appropriate.

Q: Is it true that Лоспирин is often recommended for people over 50?

A: Regulatory-endorsed guidelines regarding starting aspirin for prevention (primary prevention) generally focus on balancing risk and benefit for adults in the 40 to 59 age range. However, these same guidelines generally advise against beginning daily aspirin therapy for prevention in individuals aged 60 years or older. This decision is based on the careful balance between preventing vascular events and the increased risk of bleeding.

Q: Are there any foods or drinks I should avoid while taking Лоспирин?

A: Official product documents generally do not list specific foods that must be avoided while taking this medicine. However, it is often recommended to take the tablet with or immediately after food to help minimize potential stomach irritation. Regulatory warnings do specify that consuming alcohol, particularly three or more drinks per day, may increase the chance of gastrointestinal bleeding.

Q: Is it normal to feel a mild burning sensation when taking Лоспирин?

A: Regulatory information notes that gastrointestinal irritation, indigestion (dyspepsia), and stomach upset are common effects. A mild burning sensation can be a way of describing this type of irritation. Always ensure the tablet is swallowed whole to utilize the protective coating.

Q: Does taking Лоспирин affect blood pressure readings?

A: Official regulatory and professional guidance indicates that the active ingredient in Лоспирин can be associated with effects like fluid retention and, in some cases, high blood pressure (hypertension). Blood pressure monitoring may be considered as part of the individual risk assessment and management plan. It is also documented that aspirin can diminish the effect of some blood pressure-lowering medicines.

Q: Does Лоспирин need to be taken at a specific time of day?

A: Official product instructions state that the medicine should be taken once daily. Regulatory instructions state that the medicine should be taken with or immediately after food. There is typically no mandate in regulatory documents for a specific time of day, but consistency is generally important for continuous antiplatelet effect.

Q: Why is it important to tell my dentist I am taking Лоспирин?

A: The primary reason for informing a dentist is due to the medicine's antiplatelet action, which makes the blood less prone to clotting. Regulatory warnings stress that this effect carries a potential risk of excessive bleeding during surgical or dental procedures. Consultation with the dentist or doctor is necessary to manage potential bleeding risk during procedures.

Q: Can I take Лоспирин if I have a history of ulcers?

A: Official regulatory documents identify a history of gastrointestinal bleeding or peptic ulcer disease as a major risk factor or contraindication for using aspirin. The active ingredient can increase the risk of severe stomach bleeding, and the risk is higher if a person has had ulcers previously. A healthcare professional is responsible for evaluating the balance between benefits and risks in light of an individual’s medical history.

Q: Is Лоспирин recommended for healthy people to prevent future problems?

A: The use of this medication is designated for long-term prevention in individuals considered at high risk for serious cardiovascular events. Official evidence indicates that for low-risk populations, the benefit of prevention must be carefully weighed against the known increased risk of bleeding events. It is not generally recommended for the low-risk population.

Q: Does using Лоспирин have any effect on kidney function?

A: Regulatory warnings specify that the medicine should be used with caution if a patient has impaired kidney function. Official product information notes the potential for the active ingredient to cause effects on the kidneys, especially in certain at-risk situations like dehydration. Severe renal impairment is listed as a contraindication.

Q: If I feel fine, do I still need to take Лоспирин?

A: As this is a preventative medicine, an individual may not feel any immediate change in their health after starting it. Regulatory patient information advises that it is still working to prevent future serious events. Since the usage pattern is defined as long-term or indefinite, it is typically expected that the medicine be continued as prescribed, even in the absence of noticeable symptoms.

Q: How quickly does Лоспирин start working after I take it?

A: The antiplatelet effect of the active ingredient, which works by irreversibly blocking an enzyme in blood platelets, is generally achieved rapidly after the initial dose. According to regulatory pharmacodynamic data, the onset of this effect is quick. However, achieving the full intended blockade of platelet function throughout the entire population of circulating platelets may take a few hours to several days.

Q: Can Лоспирин affect my sleep or make me dizzy?

A: Official product documentation lists dizziness as a potential side effect. This reaction may be more prominent with higher doses of the active ingredient or in cases of accidental overdose. Insomnia or other sleep disturbances are not generally listed as common adverse reactions in the main safety summaries for this drug.

Q: Is it safe to stop taking Лоспирин suddenly?

A: Regulatory patient information explicitly advises against stopping daily low-dose aspirin therapy suddenly without consulting a healthcare professional. The continuous antiplatelet effect is essential for the preventative purpose of the medicine. Abrupt discontinuation may remove this protective effect and is associated with a potential increase in the risk of a blood clot or cardiovascular event.

Q: Does Лоспирин interact with common vitamins or supplements?

A: Official regulatory information warns that the active ingredient may interact with certain herbal supplements, including those containing ginkgo, garlic, and ginger. These interactions are noted because they can potentially increase the risk of bleeding. Patients are always advised to inform their healthcare professional about all medicines and supplements being taken, even if they are vitamins.

Q: Does having diabetes change whether I can take Лоспирин?

A: Diabetes is officially recognized as a major risk factor for vascular disease. The decision to initiate the use of this medication is determined by a healthcare professional based on a comprehensive assessment of an individual’s overall cardiovascular risk profile, which takes diabetes into account. Regulatory guidance does not list diabetes itself as a contraindication.

Q: Can I take Лоспирин before or after surgery?

A: Regulatory warnings state that this medication should not be taken shortly before or after any surgical or dental procedure unless specifically directed by a healthcare professional. This is a critical safety consideration due to the medicine's documented effect of increasing the risk of bleeding. The decision to temporarily stop or continue treatment depends on the specific procedure and the individual patient’s risk profile.

Q: What should I do if I notice a change in my stool while taking Лоспирин?

A: Official product warnings indicate that dark-colored stools or stools containing blood may be a sign of gastrointestinal bleeding, which is a documented risk of this medicine. Patient information states that if this change occurs, the medication should be discontinued and urgent medical attention should be sought.

Q: Do I need regular blood tests while I'm taking Лоспирин?

A: For typical low-dose preventative use, routine, periodic blood tests are not universally required according to official patient information. However, regulatory documents may recommend the monitoring of liver or kidney function, or checks for signs of bleeding in specific groups of at-risk patients or during long-term therapy. Any need for testing is determined by a healthcare professional.

Q: Are there any known interactions between Лоспирин and herbal medicines?

A: Official patient information frequently includes a general warning that the active ingredient may not mix well with various complementary and herbal medicines. This caution is primarily due to the potential for certain herbal products to increase the existing, documented risk of bleeding associated with the medication. Patients are always advised to list all supplements and herbal products for their healthcare provider.

Q: Do official documents mention a maximum age for taking Лоспирин?

A: Official labeling does not typically mandate a maximum age for patients who are already receiving long-term preventative therapy. However, clinical guidelines cited by health authorities advise against initiating (starting) daily aspirin therapy for primary prevention in people aged 60 years or older. Use in older adults is generally permitted but requires caution.

Q: What should I do if I accidentally take two tablets of Лоспирин?

A: Regulatory patient information suggests that taking only one or two extra tablets by mistake is unlikely to cause immediate harm. However, if a larger amount is taken or if signs of overdose occur—such as ringing in the ears, unusual confusion, or dizziness—it is important to seek medical attention.

How should Лоспирин be stored and disposed of?

How to Store and Dispose of Лоспирин?

This section outlines the official, mandatory storage and disposal rules for Lospirin (low-dose Acetylsalicylic Acid enteric-coated tablets), as defined by regulatory authorities.

Storage Requirement Official Rule
Temperature & Environment Store at room temperature (typically 15 C to 30 C) and protect from excess heat and moisture (e.g., do not store in the bathroom).
Packaging Keep the medication in the original container, maintained tightly closed.
Stability Check Discard the tablets immediately if they develop a strong vinegar-like smell, which indicates decomposition.
Child Safety Mandatory: Always store out of the sight and reach of children.

Disposal Instructions

The preferred method for discarding unused or expired Lospirin is utilizing a drug take-back program. If this option is unavailable, the product should be mixed with an undesirable substance (e.g., dirt, used coffee grounds), sealed, and placed in the household trash. The tablets must not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Лоспирин found in:

A-Z Index: